title: Heart rate reduction in heart failure: ivabradine or beta blockers?
abstract: Ivabradine, a selective I f current inhibitor, decreasing the heart rate in those with sinus rhythm, has been added to the most recent European guidelines on heart failure. It is indicated in addition to beta blockers in patients with decreased left ventricular ejection fraction and sinus rate of over 70 beats per minute. Several well-designed studies including the BEAUTIFUL and the SHIFT trials demonstrated clear benefits of ivabradine in symptomatic patients, both with angina and with heart failure, with left ventricular systolic dysfunction. The main objective of this review is to provide a comprehensive summary of data on ivabradine, and to discuss the potential role of this new agent in the spectrum of modern therapeutics for heart failure.
authors.affiliation: Department of Medicine, University of South Florida, Tampa, FL, USA. mguglin@gmail.com
authors.forename: Maya
authors.initials: M
authors.lastname: Guglin
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D001552:Benzazepines / Q000627:therapeutic use*; D002316:Cardiotonic Agents / Q000627:therapeutic use*; D005060:Europe; D019317:Evidence-Based Medicine; D006333:Heart Failure / Q000188:drug therapy* / Q000503:physiopathology; D006339:Heart Rate / Q000187:drug effects*; D006801:Humans; D000077550:Ivabradine; D017410:Practice Guidelines as Topic; D016896:Treatment Outcome
chemical_list: D000319:Adrenergic beta-Antagonists; D001552:Benzazepines; D002316:Cardiotonic Agents; D000077550:Ivabradine